Efficacy
ESPS 2: Effects on Stroke - Survival Curves (“Non-event” Probability)
| Events Prevented per 1,000 patients |
NNT |
RRR (%) | |
|---|---|---|---|
| ER-DP = Extended-Release Dipyridamole ASA = Acetylsalicylic Acid NNT = Number Needed to Treat |
|||
| ER-DP + ASA vs. Placebo | 58 |
18 |
37.0 |
| ER-DP vs. Placebo | 26 |
39 |
16.3 |
| ASA vs. Placebo | 29 |
32 |
18.1 |
| ER-DP + ASA vs. ASA | 30 |
31 |
23.1 |
These data indicate the pairwise comparisons of risk reduction interpreted as the number of strokes prevented per 1,000 patients treated for 2 years. For 1,000 patients treated with ER-DP and ASA, 58 strokes could be prevented; with ER-DP alone, 26; with ASA alone, 29. A comparison of ER-DP + ASA vs. ASA alone revealed that an additional 30 strokes per 1,000 patients were prevented by the combination therapy with ER-DP and ASA. These numbers reflect all strokes, fatal or not, but a reflect predominantly non-fatal strokes.
References
ESPS 2 Group. J Neurol Sci 1997; 151 (Suppl): S1-S77.
J Neurol Sci Abstract
